ResApp Health
ResApp Health is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ResApp Health.
ResApp Health is a company.
Key people at ResApp Health.
Key people at ResApp Health.
ResApp Health was an Australian digital health company (ASX: RAP) based in Brisbane that developed smartphone applications using machine learning to analyze cough and breathing sounds for diagnosing and managing respiratory diseases, including pneumonia, asthma, COPD, croup, bronchiolitis, and sleep apnea.[1][2][3][5] Its key products, ResAppDx and SleepCheckRx, targeted clinicians in telehealth, emergency, and primary care settings as well as consumers for at-home screening, solving the problem of accessible, low-cost point-of-care diagnostics without additional hardware—particularly in underserved regions like Africa and during challenges like COVID-19.[2][3][5] The company served doctors, patients, and partners in telehealth (e.g., Coviu, Phenix Health) and global health initiatives, achieving regulatory approvals (CE Mark in Europe, TGA in Australia, FDA for SleepCheckRx) before its acquisition by Pfizer in September 2022 for $179 million, marking strong validation of its growth momentum.[2][7]
ResApp Health originated as a University of Queensland (UQ) startup, licensing technology developed by Associate Professor Udantha Abeyratne and his team in UQ’s School of Information Technology and Electrical Engineering, in close collaboration with pediatricians and respiratory physicians.[2] The idea emerged from advancing smartphone-based sound analysis to identify respiratory conditions accurately via coughs and symptoms like runny nose, with early focus on chronic and acute diseases.[2][3] Pivotal moments included TGA approval and CE marking for ResAppDx in Australia and Europe, positive COVID-19 screening results, FDA clearance for SleepCheckRx in 2022, partnerships like Ilara Health for African diagnostics, and U.S. DoD collaboration, culminating in Pfizer's acquisition on September 26, 2022, as announced by CEO Tony Keating.[2][3][5][6][7]
ResApp rode the wave of digital biomarkers and AI-driven telehealth, accelerating during the COVID-19 pandemic with cough-based screening to reduce PCR tests and address global respiratory disease burdens—like lower respiratory tract infections causing nearly a million African deaths yearly per WHO.[2][3] Timing was ideal amid rising smartphone penetration, virtual care demand, and needs in underserved markets (e.g., 500 million Africans lacking basic diagnostics), where low-cost tools democratize high-quality care.[3] Market forces favoring ResApp included regulatory momentum (FDA, CE, TGA), telehealth expansion in Australia/Europe, and pharma interest in non-invasive diagnostics, influencing the ecosystem by pioneering sound-based AI for respiratory health and paving the way for Pfizer's broader digital health portfolio.[2][5][7]
Post-acquisition, ResApp's technology integrates into Pfizer's digital team, advancing its mission to deliver high-quality healthcare globally via apps like SleepCheckRx and ResAppDx.[2] Expect expansion in AI diagnostics for respiratory conditions, leveraging Pfizer's resources for U.S./global trials, new indications (e.g., enhanced COVID tools), and emerging trends like wearable integration or real-time monitoring amid rising chronic disease prevalence. Its influence could evolve by setting standards for accessible digital health, potentially transforming triage in low-resource settings and telehealth worldwide, building on the proven model that drew Pfizer's $179 million bet.[2][7]
